27 completed, 3 recruiting, 3 terminated, 2 active not recruiting. 22 Phase 2, 6 Phase 1, 5 Phase 3, 1 Not applicable.
Follow sipuleucel-T: new trials by email Literature Review of sipuleucel-T trials Research Report on sipuleucel-T
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer Sipuleucel-T, N803 - Prostate Cancer, Metastatic Prostate Cancer | Phase 1 | Not yet recruiting | Washington University School of Medicine | 30 | 2026-11-30 | 2026-08-10 |
| 177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer Biospecimen Collection, Bone Scan, Computed Tomography - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 1 | Recruiting | City of Hope Medical Center | 30 | 2026-03-06 | 2026-04-20 |
| Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC Testosterone Cypionate, Sipuleucel-T - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | Yale University | 26 | 2023-12-20 | 2026-09-10 |
| Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer Sipuleucel-T - Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 1 | Active not recruiting | University of Oklahoma | 15 | 2023-11-12 | 2026-05-27 |
| Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T Sipuleucel-T Injection - Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 2 | Recruiting | Dendreon | 400 | 2023-10-02 | 2025-08-27 |
| Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer Abiraterone, Enzalutamide, Apalutamide - Prostate Cancer, Metastatic Prostate Cancer | Phase 2 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 26 | 2023-02-14 | 2026-09-15 |
| Tonsil Surgery in Recurrent or Chronic Tonsillitis Tonsillectomy, Tonsillotomy - Tonsillitis Recurrent, Tonsillitis Chronic | Not applicable | Completed | Oulu University Hospital | 147 | 2020-12-08 | 2023-06-12 |
| Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer sipuleucel-T - Adenocarcinoma of the Prostate | Phase 3 | Completed | Dendreon | 532 | 2018-10-18 | 2024-10-08 |
| Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer Atezolizumab1200 mg IV, Sipuleucel-T - Prostate Cancer Metastatic | Phase 1 | Completed | University of Hawaii | 37 | 2017-02-06 | 2021-05-26 |
| Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer Sipuleucel-T, Docetaxel - Prostate Cancer | Phase 2 | Withdrawn | The University of Texas Health Science Center, Houston | 2016-12-01 | 2017-10-30 | |
| Docetaxel Followed by Provenge in Metastatic Prostate Cancer Docetaxel, Sipuleucel-T - Prostate Cancer | Phase 2 | Withdrawn | The University of Texas Health Science Center, Houston | 2016-12-01 | 2017-10-30 | |
| Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC Radium-223, Sipuleucel-T - Prostate Cancer | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 36 | 2016-02-22 | 2021-07-08 |
| Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise Testing Enzalutamide, Abiraterone acetate, Sipuleucel-T - Prostate Cancer | Completed | Duke University | 38 | 2015-07-07 | 2020-12-24 | |
| Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Laboratory Biomarker Analysis, Sipuleucel-T, Tasquinimod - Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma | Phase 2 | Completed | Roswell Park Cancer Institute | 2 | 2015-01-01 | 2023-04-27 |
| A Multicenter Trial Enrolling Men With Advanced Prostate Cancer Who Are to Receive Combination Radiation and Sipuleucel-T Provenge - Castrate Refractory Metastatic Prostate Cancer (mCRPC) | Completed | GenesisCare USA | 20 | 2014-06-01 | 2019-01-09 | |
| Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer SipT Treatment, Ipilimumab - Prostate Cancer | Phase 2 | Completed | University of California, San Francisco | 50 | 2014-04-22 | 2021-08-18 |
| Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer Sipuleucel-T, Lymph Node Biopsy - Prostate Cancer | Phase 1 | Completed | Duke University | 20 | 2014-03-01 | 2020-03-31 |
| A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer sipuleucel-T, enzalutamide - Metastatic Prostate Cancer | Phase 2 | Completed | Dendreon | 52 | 2013-09-01 | 2018-10-24 |
| Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC) Sipuleucel-T, Stereotactic Ablative Body Radiation - Metastatic Castrate-resistant Prostate Cancer, mCRPC | Phase 2 | Completed | University of Texas Southwestern Medical Center | 20 | 2013-07-10 | 2022-05-06 |
| Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer sipuleucel-T, external beam radiation therapy, laboratory biomarker analysis - Adenocarcinoma of the Prostate, Bone Metastases | Phase 2 | Completed | City of Hope Medical Center | 51 | 2013-06-25 | 2026-09-11 |
Showing 20 of 38. Sign in to see all of them.
Prostatic Neoplasms (29) · Neoplasm Metastasis (3) · Neoplasms (3) · Adenocarcinoma (1) · Carcinoma (1) · Genital Neoplasms, Male (1) · Neoplasms, Glandular and Epithelial (1) · Prostatic Diseases (1) · Tonsillitis (1) · Urogenital Neoplasms (1)
Dendreon (16) · City of Hope Medical Center (2) · Duke University (2) · The University of Texas Health Science Center, Houston (2) · Augusta University (1) · GenesisCare USA (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Masonic Cancer Center, University of Minnesota (1) · National Cancer Institute (NCI) (1) · Oulu University Hospital (1) · Prostate Oncology Specialists, Inc. (1) · Roswell Park Cancer Institute (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · University of California, San Francisco (1) · University of Hawaii (1)
United States (35) · Austria (1) · Canada (1) · Finland (1) · France (1) · Netherlands (1) · United Kingdom (1)
Robert Israel, MD (6) · Bruce Brown, MD (3) · Eric J. Small, MD (2) · Nadeem Sheikh, PhD (2) · Robert J Amato, DO (2) · Aleksi EJ Laajala, MD (1) · Alex Chehrazi-Raffle, MD (1) · Andrew Stubbs, PhD (1) · Andy Sandler, MD (1) · Benjamin Lowentritt, MD (1) · Brant Inman, MD (1) · Cy Stein, MD, PhD (1) · Douglas McNeel, M.D., PhD (1) · Emmanuel Antonarakis, MD (1)
PMID 24957547, PMID 35812443, PMID 37058234, PMID 16809734, PMID 20818862, PMID 23253957, PMID 23896100, PMID 27216195, PMID 29534736, PMID 30682445, PMID 32111923, PMID 33451978, PMID 33986125, PMID 34376554, PMID 35027313, PMID 35145218
P30CA033572 (1)